Abstract
The clinical efficacy of immunotherapy in acute myeloid leukemia (AML) remains significantly limited by early relapse and treatment-associated toxicities. This review examines recent advances in antibody- and cell-based immunotherapies for AML, focusing on established targets (CD33, CD123, and CLL1) as well as emerging targets (including CD7, CD70, CD38, and FLT3). Therapeutic modalities discussed include immunoconjugates, bispecific T-cell engagers and chimeric antigen receptor T (CAR-T) cells. Furthermore, we summarize the current challenges impeding the success of immunotherapy in AML and propose strategies to enhance its efficacy. These include combination therapies, structural optimization of CAR constructs, functional enhancement of CAR-T cells, identification of novel targets, and the development of next-generation cellular therapies. Collectively, these approaches aim to offer new insights for improving immunotherapeutic outcomes in AML.